Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wolf, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wolf, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 8:S71-S75, 1997
© 1997 European Society for Medical Oncology

Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma

M. Wolf1, J. P. Matthews1, J. Stone1, I. A. Cooper1, T. I. Robertson2 for the Australian and New Zealand Lymphoma Group, R. M Fox3 for the Australian and New Zealand Lymphoma Group

1 Peter MacCallum Cancer Institute Melbourne
2 Westmead Hospital Sydney
3 Royal Melbourne Hospital Melbourne, Australia

1Correspondence to: Dr. Max Wolf Division of Haematology and Medical Oncology Peter MacCallum Cancer Institute St. Andrew's Place East Melbourne, Victoria 3002 Australia

Background The initial publication of the results of the Australian and New Zealand Lymphoma Group (ANZLG) randomized controlled trial comparing MACOP-B and CHOP in patients with intermediate-grade non-Hodgkin's lymphoma (NHL) showed equivalent complete response rates, time to treatment failure, and survival. Here we report the long-term follow-up of the 236 patients entered on that study to determine if there were any long-term advantages or disadvantages associated with MACOP-B.

Patients and methods Two hundred thirty-six eligible patients were randomized between October 1986 and June 1991. The median duration of follow-up has been extended from 3.2 years in our previous publication to 6.5 years.

Results As previously reported, the complete response (CR) rate for MACOP-B and CHOP chemotherapy was 51% and 59%, respectively. The estimated failure-free survival rate for MACOP-B and CHOP patients was 42% and 30%, respectively, at 5 years (P = 0.045) and 37% and 25%, respectively, at 8 years (P = 0.057). The estimated overall survival rate at 5 years was 54% for MACOP-B and 41% for CHOP patients (P = 0.035) and at 8 years was 45% and 36%, respectively (P = 0.16).

Conclusions With this extended follow-up, we have shown a long-term survival advantage for MACOP-B chemotherapy over standard CHOP in patients with intermediate-grade non-Hodgkin's lymphoma.

chemotherapy, dose intensification, long-term survival, MACOP-B, non-Hodgkin's lymphoma, randomized trial


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
H.A. Azim, L. Santoro, R.G. Bociek, S. Gandini, R.A. Malek, and H.A. Azim Jr
High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis
Ann. Onc., October 22, 2009; (2009) mdp425v1.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.